Ann Falsey, MD
Infectious Disease · Rochester, NYNPI 1093740532
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi Pasteur Inc. accounts for 68.0% of it on its own, with 11 other manufacturers making up the rest. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $1855.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$92K
- GSK$15K
- Pfizer$11K
- Astrazeneca UK Limited$5K
- AstraZeneca$5K
- Janssen Global Services, LLC$3K
- plus $5K from 6 others
Across 82 payments — averaging $20,616 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$897K
- Merck$297K
- AstraZeneca$192K
- Pfizer$192K
- Biofire Diagnostics, LLC$87K
- Biomerieux Inc$21K
- plus $6K from 2 others
What the payments were for
- Consulting fees$43,81932%
- Speaking & faculty fees$65,99549%
- Travel & lodging$23,28617%
- Food & beverage$2,2202%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 18 | $92,059 |
| GSK | 14 | $14,627 |
| Pfizer | 11 | $11,117 |
| Astrazeneca UK Limited | 2 | $5,005 |
| AstraZeneca | 6 | $4,853 |
| Janssen Global Services, LLC | 4 | $2,629 |
| Merck | 2 | $2,126 |
| Gilead | 5 | $1,426 |
| Abbott | 1 | $1,125 |
| Modernatx, Inc. | 7 | $272 |
| Astellas Pharma US Inc | 2 | $145 |
| ADMA Biomanufacturing LLC | 1 | $82 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABRYSVO$9,407
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE$1,127
How this compares
$135,465 in reported general payments places this provider in the 95th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Rochester
- Edward WalshRochester$86K
- Emil LeshoRochester$68K
- Michael MancenidoRochester$32K
- William ValentiRochester$22K
- Harish MoorjaniBriarcliff Manor$733K
- Sorana Segal MaurerFlushing$598K
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Andre BrutusBrooklyn$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.